(S)-1-(benzyloxy)-3-phenylpropan-2-amine | 83053-86-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-1-(benzyloxy)-3-phenylpropan-2-amine
• 英文别名: (S)-2-amino-3-phenylpropyl benzyl ether；(S)-phenylalaninol benzyl ether；L-phenylalaninol benzyl ether；O-benzyl-L-phenylalaninol；(2S)-1-phenyl-3-phenylmethoxypropan-2-amine
• CAS: 83053-86-5
• 化学式: C₁₆H₁₉NO
• 分子量: 241.333
• InChiKey: WTTMVTUTZZPLGZ-INIZCTEOSA-N

物化性质

• 沸点：
  383.8±30.0 °C(Predicted)
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-1-(benzyloxy)-3-phenylpropan-2-amine 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 26.0h， 生成
  参考文献：
  名称：

  Preparation of chiral 1,2,4-triazolium salts as new NHC precatalysts

  摘要：

  The preparation of new chiral N,N'-disubstituted 1,2,4-triazolium based NHC salt precursors, Ia' and Ib, from phenylhydrazine and L-phenylalanine is reported. The 1,3,4-trisubstituted triazolium salt Ia' was obtained by a stepwise ring construction from L-phenylalanine via the corresponding imino ether and acetohydrazonamide, while a heterocyclic O-/N-heteroatom exchange strategy, based on a ring-opening/ring-closure of the oxadiazolium precursor, afforded the 1,4-disubstituted 1.2,4-triazolium salt Ib. The need for two different synthetic strategies is discussed. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2012.06.002
• 作为产物：
  描述：

  2-[(2S)-1-羟基-3-苯基丙烷-2-基]异吲哚-1,3-二酮 在 二苯并-18-冠醚-6 、 potassium hydride 、 肼 作用下， 以 乙醇 、 水 为溶剂， 反应 51.0h， 生成 (S)-1-(benzyloxy)-3-phenylpropan-2-amine
  参考文献：
  名称：

  Polymer supported enantioselective reactions. II. α-Methylation of cyclohexanone

  摘要：

  聚苯乙烯和1% 二乙烯苯交联的不溶性共聚物，具有共价键合的(S)-2-氨基烷氧基基团，用于通过相应的亚胺对环己酮进行选择性α-甲基化。在20°C下甲基化后观察到(S)-2-甲基环己酮的对映体过量达94%。在其他条件相同的情况下，类似的光学活性2-氨基烷基苄醚在-78°C时产生较低的对映体过量（49%），其选择性接近于聚合物，但只有在-78°C时才能接近。

  DOI：

  10.1139/v82-254

文献信息

• NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150023989A1

  公开（公告）日：2015-01-22

  The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.

  本申请涉及针对FGFR2靶点的新抗体药物结合物（ADCs），所述ADCs的药物代谢产物，生产所述ADCs的方法，利用所述ADCs治疗和/或预防疾病以及利用所述ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病如癌症。这种治疗可以作为单药疗法进行，也可以与其他药物或额外的治疗措施结合使用。
• NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150246136A1

  公开（公告）日：2015-09-03

  The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.

  本专利申请涉及针对靶向表皮生长因子受体（EGFR，基因ID 1956）的新型结合物-药物共轭物（ADCs）N，N-二烷基月桂酰基蛋白酶抑制剂，这些ADCs的有效代谢物，生产这些ADCs的方法，利用这些ADCs治疗和/或预防疾病，以及利用这些ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病，如癌症。这种治疗可以作为单药疗法或与其他药物或其他治疗措施联合使用。
• First Total Synthesis of Mer-N5075A, A New HIV-I Protease Inhibitor from<i>Streptomyces Chromofuscus</i>
  作者：Yaeko Konda、Yukihiro Takahashi、Hiroka Mita、Kazuyoshi Takeda、Yoshihiro Harigaya

  DOI：10.1246/cl.1997.345

  日期：1997.4

  The first total synthesis of Mer-N5075A (1), a new potential HIV-I protease inhibitor produced from Streptomyces Chromofuscus, was achieved. The synthetic method is available for Mer-N5075A analogues such as α-MAPI (2), GE20372 A (4) and other chemcally modified compounds.

  由色褐链霉菌产生的全新潜在HIV-I蛋白酶抑制剂Mer-N5075A（1）的首次全合成得以实现。该合成方法适用于Mer-N5075A类似物，如α-MAPI（2）、GE20372A（4）及其他化学修饰化合物。
• [EN] HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEUR UTILISATION COMME MÉDICAMENTS THÉRAPEUTIQUES
  申请人：DONG-A SOCIO HOLDINGS CO LTD

  公开号：WO2017039331A1

  公开（公告）日：2017-03-09

  The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.

  本发明提供了一种杂环化合物、其立体异构体、对映异构体或药用可接受的盐，这些化合物能够调节Mer受体酪氨酸激酶（MERTK）的活性。本发明还提供了这些化合物的药物组合物、制备所述化合物的方法以及将这些化合物用作药物的应用。本发明针对的是具有显著活性的MERTK抑制性化合物，因此具有在癌症和任何与MERTK调控失调相关的疾病中进行药物干预的卓越潜力。
• [EN] TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION<br/>[FR] ANALOGUES DE LA TUBULYSINE ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：PFIZER

  公开号：WO2017134547A1

  公开（公告）日：2017-08-10

  The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.

  本发明涉及新的细胞毒性的管素类似物和衍生物，以及它们的抗体药物偶联物，以及使用它们治疗包括癌症在内的医疗状况的方法。